Institute of Life Science 1 internal Atrium view up

Dr Jonathan Mullins

Associate Professor, Biomedical Sciences

Telephone number

+44 (0) 1792 513569

Welsh language proficiency

Fluent Welsh Speaker

Research Links

Academic Office - 135
First Floor
Institute of Life Science 1
Singleton Campus
Available For Postgraduate Supervision


Jonathan is an expert in computation of the structure, function and interactions of proteins (receptors, transporters, enzymes etc.) at whole genome / proteome scale, and linking this to health and disease and drug discovery. He heads up a research group and spin-out company at Swansea University Medical School, working on innovative academic research and commercial R&D in Structural Bioinformatics, applied to a broad range of biological problems, including a current Innovate UK funded project focused on development of an antiviral drug screening platform for Covid-19.  The research is getting ahead of the virus by modelling hypothetical variants and structural changes, targeting new strains before they happen.  

Areas Of Expertise

  • Structural Bioinformatics
  • Artificial Intelligence
  • Supercomputing
  • Drug Discovery
  • Platform Development
  • Health Data Research
  • Covid-19

Career Highlights

Teaching Interests

Jonathan lectures on the Graduate Entry Medicine course (biochemistry, metabolism, genetics, physiology, and molecular pathology – particularly relating to the intestine, and leads the Nutrition theme). He also teaches on the Physician Associate programme (endocrinology), the BSc Genetics / Biochemistry course (bioinformatics) and BSc Applied Medical Sciences (neuroendocrinology) and supervises third year projects for those courses.


Jonathan has an international collaborative network focussed on computational investigation of protein structure and function, and recent projects with industry including cutting-edge projects with UK MoD, Unilever plc, Air Liquide, NC3Rs and the NHS. Many journal publications, have resulted from the development of structural prediction and molecular docking algorithms and software, and the Sequence-Structure-Function-Phenotype approach featured in many studies has provided a real-world validation of the structural modelling pipelines in biomedical research and drug discovery.  
In recent years, his team has developed the Human3DProteome platform (, the first technology to offer structurally-based open-ended lead discovery, pharmacological profiling and toxicity screening applied to every protein in the human body, including 3D molecular structures for polymorphic variant proteins, the largest structural library of human disease phenotypes in existence, and a powerful tool in the study of the genetic causation of disease. 


Dr Helena Castro and Dr Marcos Vinicius Santana (Universidade Federal Fluminense, Rio de Janeiro)  
Dr Seo-Kyung Chung (University of Sydney) 
Prof. Gwyn Gould (Strathclyde University) 
Prof. Bill Griffiths (Swansea University) 
Prof. Steve Kelly (Swansea University) 
Dr Aik Jiang Lau (National University of Singapore) 
Prof. Martin Sheldon (Swansea University) 
Prof. Yuqin Wang (Swansea University)